CRISPR-Cas9: A New Frontier in the Treatment and Research of Cardiovascular Diseases

Jinnan Jiao

2025

Abstract

CRISPR-Cas9 provides accurate and effective techniques for altering genetic sequences, revolutionizing the field of genome editing, which holds significant potential for treating cardiovascular diseases (CVD) by correcting pathogenic mutations and modulating gene expression. LDLR gene mutations have been successfully corrected using CRISPR-Cas9, which is associated with familial hypercholesterolemia, thereby improving the atherosclerotic phenotype in mouse models. Additionally, CRISPR-Cas9 shows promise in treating familial cardiomyopathies by correcting mutations in genes such as RBM20 and MYH6, leading to the restoration of normal cardiac function. However, several challenges remain, including off-target effects, which leads to unintended genetic alterations, and delivery challenges that limit the precise targeting of cardiovascular tissues. The creation of innovative delivery systems, like lipid nanoparticles, is one area of future research, to enhance specificity and reduce off-target effects. Personalized medicine may benefit from the combination of CRISPR-Cas9 and next-generation sequencing, which could result in the development of CVD cures.

Paper Citation

in Harvard Style

Jiao J. (2025). CRISPR-Cas9: A New Frontier in the Treatment and Research of Cardiovascular Diseases. In Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS; ISBN 978-989-758-789-4, SciTePress, pages 362-367. DOI: 10.5220/0014493400004933

in Bibtex Style

@conference{befs25,
author={Jinnan Jiao},
title={CRISPR-Cas9: A New Frontier in the Treatment and Research of Cardiovascular Diseases},
booktitle={Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS},
year={2025},
pages={362-367},
publisher={SciTePress},
organization={INSTICC},
doi={10.5220/0014493400004933},
isbn={978-989-758-789-4},
}

in EndNote Style

TY - CONF

JO - Proceedings of the 1st International Conference on Biomedical Engineering and Food Science - Volume 1: BEFS
TI - CRISPR-Cas9: A New Frontier in the Treatment and Research of Cardiovascular Diseases
SN - 978-989-758-789-4
AU - Jiao J.
PY - 2025
SP - 362
EP - 367
DO - 10.5220/0014493400004933
PB - SciTePress